Literature DB >> 33573630

The impact of thrombocytopenia on prognosis of HBV-related small hepatocellular carcinoma: a propensity score matching analysis.

Wei Peng1, Chuan Li1, Xiaoyun Zhang1, Tianfu Wen1, Zheyu Chen2.   

Abstract

BACKGROUND: Thrombocytopenia was reported both detrimental and advantageous to hepatocellular carcinoma (HCC). However, there is little evidence showing clearly the clinical value of preoperative thrombocytopenia on the surgical outcome of patients with small HCC. This retrospective study aimed at elucidating the correlation between preoperative thrombocytopenia and surgical outcome of small HCC patients within Milan criteria treated with liver resection.
METHODS: Data of hepatitis B virus (HBV)-related small HCC patients were retrospectively analyzed, and we performed the propensity score matching (PSM) analysis to overcome the imbalance of clinicopathological features. Patients enrolled were subsequently categorized into two groups according to preoperative platelet counts: thrombocytopenia group and non-thrombocytopenia group. Survival outcomes of the patients in both groups were described with the Kaplan-Meier method, and the difference was compared with a log-rank test. Cox regression analysis was applied to identify the risk factors of surgical outcome.
RESULTS: After PSM, the estimated 1-, 3-, and 5-year overall survival (OS) rates for small HCC patients in the thrombocytopenia group were 94.5%, 77.0%, and 57.6%, and 95.0%, 79.6%, and 68.0%, respectively, for small HCC patients in the non-thrombocytopenia group (P = 0.042). And the 1-, 3-, and 5-year estimated recurrence-free survival (RFS) rates for small HCC patients in the thrombocytopenia group were 70.4%, 51.0%, and 42.1%, and 83.8%, 63.7%, and 46.7%, respectively, for small HCC patients in the non-thrombocytopenia group (P = 0.035). Multivariate analysis indicated preoperative thrombocytopenia was a significant prognosticator of poor RFS (hazard ratio (HR) = 1.388, 95% confidence interval (CI) 1.028~1.874, P = 0.033).
CONCLUSION: Preoperative thrombocytopenia had an undesirable impact on the recurrence of small HCC patients treated with liver resection.

Entities:  

Keywords:  Hepatocellular carcinoma; Liver resection; Platelet; Thrombocytopenia

Mesh:

Year:  2021        PMID: 33573630      PMCID: PMC7879633          DOI: 10.1186/s12957-021-02160-2

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   2.754


  39 in total

1.  Significance of platelet count in the outcomes of hepatectomized patients with hepatocellular carcinoma exceeding the Milan criteria.

Authors:  Hironobu Amano; Hirotaka Tashiro; Akihiko Oshita; Tsuyoshi Kobayashi; Yoshisato Tanimoto; Shintaro Kuroda; Hirofumi Tazawa; Toshiyuki Itamoto; Toshimasa Asahara; Hideki Ohdan
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

2.  Antiplatelet therapy and the risk of hepatocellular carcinoma in chronic hepatitis B patients on antiviral treatment.

Authors:  Minjong Lee; Goh Eun Chung; Jeong-Hoon Lee; Sohee Oh; Joon Yeul Nam; Young Chang; Hyeki Cho; Hongkeun Ahn; Young Youn Cho; Jeong-Ju Yoo; Yuri Cho; Dong Hyeon Lee; Eun Ju Cho; Su Jong Yu; Dong Ho Lee; Jeong Min Lee; Yoon Jun Kim; Jung-Hwan Yoon
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

3.  Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis.

Authors:  A Kaser; G Brandacher; W Steurer; S Kaser; F A Offner; H Zoller; I Theurl; W Widder; C Molnar; O Ludwiczek; M B Atkins; J W Mier; H Tilg
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

4.  Revisiting the role of nonanatomic resection of small (< or = 4 cm) and single hepatocellular carcinoma in patients with well-preserved liver function.

Authors:  Chang Moo Kang; Gi Hong Choi; Dong Hyun Kim; Sae Byeol Choi; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee
Journal:  J Surg Res       Date:  2009-02-21       Impact factor: 2.192

5.  High platelet counts increase metastatic risk in huge hepatocellular carcinoma undergoing transarterial chemoembolization.

Authors:  Tong-Chun Xue; Ning-Ling Ge; Xin Xu; Fan Le; Bo-Heng Zhang; Yan-Hong Wang
Journal:  Hepatol Res       Date:  2016-03-10       Impact factor: 4.288

6.  Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection.

Authors:  Edoardo Giannini; Federica Botta; Paolo Borro; Federica Malfatti; Alessandra Fumagalli; Emanuela Testa; Elena Podestà; Bruno Chiarbonello; Simone Polegato; Mario Mamone; Roberto Testa
Journal:  Am J Gastroenterol       Date:  2003-11       Impact factor: 10.864

Review 7.  Thrombocytopenia associated with chronic liver disease.

Authors:  Nezam Afdhal; John McHutchison; Robert Brown; Ira Jacobson; Michael Manns; Fred Poordad; Babette Weksler; Rafael Esteban
Journal:  J Hepatol       Date:  2008-03-31       Impact factor: 25.083

Review 8.  Management of thrombocytopenia due to liver cirrhosis: a review.

Authors:  Hiromitsu Hayashi; Toru Beppu; Ken Shirabe; Yoshihiko Maehara; Hideo Baba
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

9.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

10.  Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma.

Authors:  Bernhard Scheiner; Martha Kirstein; Sabine Popp; Florian Hucke; Simona Bota; Nataliya Rohr-Udilova; Thomas Reiberger; Christian Müller; Michael Trauner; Markus Peck-Radosavljevic; Arndt Vogel; Wolfgang Sieghart; Matthias Pinter
Journal:  Liver Cancer       Date:  2018-06-22       Impact factor: 11.740

View more
  4 in total

1.  Deep-learning-based analysis of preoperative MRI predicts microvascular invasion and outcome in hepatocellular carcinoma.

Authors:  Bao-Ye Sun; Pei-Yi Gu; Ruo-Yu Guan; Cheng Zhou; Jian-Wei Lu; Zhang-Fu Yang; Chao Pan; Pei-Yun Zhou; Ya-Ping Zhu; Jia-Rui Li; Zhu-Tao Wang; Shan-Shan Gao; Wei Gan; Yong Yi; Ye Luo; Shuang-Jian Qiu
Journal:  World J Surg Oncol       Date:  2022-06-08       Impact factor: 3.253

2.  Development and validation of nomogram to predict very early recurrence of combined hepatocellular-cholangiocarcinoma after hepatic resection: a multi-institutional study.

Authors:  Yijun Wu; Hongzhi Liu; Jianxing Zeng; Yifan Chen; Guoxu Fang; Jinyu Zhang; Weiping Zhou; Yongyi Zeng; Jingfeng Liu
Journal:  World J Surg Oncol       Date:  2022-02-28       Impact factor: 2.754

3.  The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis.

Authors:  Anan Gong; Xiaofei Li
Journal:  World J Surg Oncol       Date:  2022-03-04       Impact factor: 2.754

4.  Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study.

Authors:  Fuqun Wei; Qizhen Huang; Yang Zhou; Liuping Luo; Yongyi Zeng
Journal:  World J Surg Oncol       Date:  2021-06-14       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.